6533b7d3fe1ef96bd1260ba6
RESEARCH PRODUCT
Common Neural Mechanisms of Palatable Food Intake and Drug Abuse: Knowledge Obtained with Animal Models
María Del Carmen Blanco-gandíaMarta Rodríguez-ariasJosé Miñarrosubject
DrugDrugs of abuseFood intakeSubstance-Related Disordersmedia_common.quotation_subjectDevelopmental psychologyEating03 medical and health sciences0302 clinical medicineRewardDrug DiscoverymedicineAnimalsHumans030304 developmental biologymedia_commonPharmacology0303 health sciencesAddictionFeeding Behaviormedicine.diseaseComorbidityObesitySubstance abuseEating disordersModels AnimalPsychology030217 neurology & neurosurgerydescription
Eating is necessary for survival, but it is also one of the great pleasures enjoyed by human beings. Research to date shows that palatable food can be rewarding in a similar way to drugs of abuse, indicating considerable comorbidity between eating disorders and substance-use disorders. Analysis of the common characteristics of both types of disorder has led to a new wave of studies proposing a Gateway Theory of food as a vulnerability factor that modulates the development of drug addiction. The homeostatic and hedonic mechanisms of feeding overlap with some of the mechanisms implicated in drug abuse and their interaction plays a crucial role in the development of drug addiction. Studies in animal models have shown how palatable food sensitizes the reward circuit and makes individuals more sensitive to other substances of abuse, such as cocaine or alcohol. However, when palatable food is administered continuously as a model of obesity, the consequences are different, and studies provide controversial data. In the present review, we will cover the main homeostatic and hedonic mechanisms that regulate palatable food intake behavior and will explain, using animal models, how different types of diet and their intake patterns have direct consequences on the rewarding effects of psychostimulants and ethanol.
year | journal | country | edition | language |
---|---|---|---|---|
2019-10-29 | Current Pharmaceutical Design |